Close

Executive Committee & Governing Boards

The Biotechnology Innovation Organization (BIO) is governed by the Executive Committee.  This committee consists of the seven Elected Officers of the Organization, the immediate Past Chair of the Organization, the Vice Chairs of each Section's Governing Board, and At-Large Directors selected from the Full Board by the Chair and approved by the Board. The committee is authorized to exercise all powers of the Full Board, except for certain powers reserved for the Full Board under BIO's Bylaws. The BIO Board of Directors is comprised of all members of the Section Governing Boards.

BIO also has four Section Governing Boards who bring their opinion to bear on major issues affecting their specific area of biotechnology.  The four Section Governing Boards are Emerging Companies, Food & Agriculture, Health and Industrial & Environmental. 

Below are the staff contacts for the executive committee and each governing board.
Executive Committee: Tom DiLenge
Emerging Companies Section Governing Board: Cartier Esham
Food & Agriculture Section Governing Board: Dana O’Brien
Health Section Governing Board: Dan Durham
Industrial & Environmental Section Governing Board: Brent Erickson

Executive Committee

Executive Committee

  • Ron Cohen, MD Chair
    President & CEO, Acorda Therapeutics, Inc
  • Bradford A. Zakes, MBA Treasurer
    Chief Executive Officer, Cerevast Therapeutics, Inc
  • David P. Meeker, MD Secretary
    Chief Executive Officer, Genzyme Corporation, A Sanofi Company
  • Alex M. Azar II
    President of Lilly USA, Eli Lilly and Company
  • Ian T. Clark
    CEO & Head of North American Commercial Operations, Genentech, Genentech, A Member of the Roche Group
  • Tjerk de Ruiter
    Chief Executive Officer, Corbion
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Julie L. Gerberding, MD, MPH
    EVP, Strategic Communications, Global Public Policy, and Population Health, Merck
  • Paul J. Hastings
    Chairman and CEO, OncoMed Pharmaceuticals, Inc
  • Perry Karsen
    Chairman of the Board, Jounce Therapeutics, Inc.
  • Rachel K. King
    President & CEO, GlycoMimetics, Inc
  • John Maraganore, PhD
    Chief Executive Officer, Alnylam Pharmaceuticals, Inc
  • Michael Narachi
    President and CEO, Orexigen Therapeutics, Inc
  • Richard Pops
    Chairman & CEO, Alkermes, Inc.
  • Alan Shaw, PhD
    President & CEO, Calysta
  • Jay P. Siegel, MD
    Chief Biotechnology Officer & Head, Scientific Strategy & Policy, Johnson & Johnson
  • Eddie J. Sullivan, PhD
    President & CEO, SAB Biotherapeutics
  • Section Governing Boards

    Emerging Companies Section Governing Board

  • Michael Narachi Chair
    President and CEO, Orexigen Therapeutics, Inc
  • Jeffrey S. Hatfield Secretary
    Chief Executive Officer, Vitae Pharmaceuticals, Inc
  • Martin Babler
    Chief Executive Officer, Principia Biopharma
  • Katrine Bosley
    Chief Executive Officer, Editas Medicine
  • Jeffrey L. Cleland
    President & CEO, Gray Bug, Inc.
  • Ron Cohen, MD
    President & CEO, Acorda Therapeutics, Inc
  • John F. Crowley, JD, MBA
    President & CEO, Amicus Therapeutics, Inc
  • Michelle Dipp, MD, PhD
    Chief Executive Officer, OvaScience, Inc.
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Jean-Francois Formela, MD
    Partner, Atlas Venture Life Sciences Advisors
  • Maxine Gowen, PhD
    President & CEO, Trevena, Inc.
  • Peter S. Greenleaf
    Chairman & CEO, Sucampo Pharmaceuticals, Inc
  • Paul J. Hastings
    Chairman and CEO, OncoMed Pharmaceuticals, Inc
  • James Healy, MD, PhD
    General Partner, Sofinnova Ventures
  • Russell H. Herndon
    President & CEO, Hydra Biosciences, Inc
  • Emil D. Kakkis, MD, PhD
    Chief Executive Officer & President, Ultragenyx Pharmaceutical, Inc
  • Perry Karsen
    Chairman of the Board, Jounce Therapeutics, Inc.
  • Rachel K. King
    President & CEO, GlycoMimetics, Inc
  • Scott Koenig, MD, PhD
    President & CEO, MacroGenics, Inc
  • Jonathan Leff
    Chairman, Deerfield Institute, and Partner Deerfield Management , Deerfield Management Company LP
  • Nick Leschly
    President & Chief Executive Officer, bluebird bio
  • Jeremy M. Levin , DPHIL,MB,BCHIR
    Chairman & CEO, Ovid Therapeutics Inc.
  • Bill Lis
    Chief Executive Officer , Portola Pharmaceuticals, Inc
  • David Main
    President & CEO, Aquinox Pharmaceuticals, Inc.
  • John Maraganore, PhD
    Chief Executive Officer, Alnylam Pharmaceuticals, Inc
  • Joel S. Marcus
    Chief Executive Officer, Alexandria Real Estate Equities, Inc
  • Thomas P. Mathers
    Chief Executive Officer, CoLucid Pharmaceuticals, Inc
  • John Mendlein, PhD
    President, CEO & Chairman, aTyr Pharma, Inc.
  • Steven J. Mento, PhD
    President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
  • William J. Newell
    Chief Executive Officer, Sutro Biopharma, Inc
  • Christian W. Nolet
    Partner & Area Leader, Life Sciences, Ernst & Young, LLP
  • John A. Orwin
    President & CEO, Relypsa, Inc
  • Steven Paul
    President & CEO, Voyager Therapeutics, Inc.
  • Carlos V. Paya, MD, PhD
    Chief Executive Officer, Immune Design Corporation
  • Adelene Q. Perkins
    President & CEO, Infinity Pharmaceuticals, Inc.
  • Mark Pruzanski, MD
    Founder, President & CEO, Intercept Pharmaceuticals, Inc
  • Michael G. Raab
    Chief Executive Officer, Ardelyx Inc.
  • James Sapirstein, RPh, MBA
    Chief Executive Officer, Contravir Pharmaceuticals
  • Nancy Simonian, MD
    Chief Executive Officer, Syros Pharmaceuticals
  • Moncef Slaoui, PhD
    Chairman of GSK Vaccines, GlaxoSmithKline plc
  • Julie A. Smith
    President & CEO, Raptor Pharmaceutical Corporation
  • David M. Stack
    President & CEO, Pacira Pharmaceuticals, Inc.
  • Gil Van Bokkelen, PhD
    Chairman & CEO, Athersys, Inc
  • Harold E. Van Wart, PhD
    President, CEO & Director, CymaBay Therapeutics
  • Timothy P. Walbert
    Chairman, President & CEO, Horizon Pharma, plc
  • Neil K. Warma
    President & CEO, Opexa Therapeutics
  • Christoph H. Westphal, MD, PhD
    Chairman/CEO, Verastem
  • Robert J. Wills, PhD
    VP, Alliance Management - Business Development, Pharma Group, GTx, Inc
  • Bradford A. Zakes, MBA
    Chief Executive Officer, Cerevast Therapeutics, Inc
  • Food & Agriculture Section Governing Board

  • Eddie J. Sullivan, PhD Food & Ag Section Chair
    President & CEO, SAB Biotherapeutics
  • Philip W. Miller Food & Ag Section Vice Chair
    Global Regulatory & Government Affairs Lead, Monsanto Company
  • Brian Barker
    General Manager - US Seeds, Dow AgroSciences, LLC
  • Jack Bernens
    Head of Enogen, Syngenta
  • Jerry Flint
    Vice President of the Industry Affairs & Regulatory Group, Dupont Corporation
  • Scott Holmstrom
    Senior Director, Late Stage External Innovation, Elanco Animal Health, A Division of Eli Lilly & Co.
  • Dan Meagher
    President & CEO, Agrivida, Inc
  • Daphne Preuss, PhD
    President & CEO, Chromatin, Inc
  • Ronald L. Stotish, PhD
    Chief Executive Officer, Aqua Bounty Technologies, Inc
  • John R. Swart, PhD
    President, Exemplar Genetics, LLC
  • Frank Terhorst
    Global Head of Seeds, Bayer CropScience, Inc.
  • Rick Van Genderen
    DIRECTOR, GLOBAL VALUE CHAIN, BASF Plant Science LP
  • Health Section Governing Board

  • Ron Cohen, MD Chair
    President & CEO, Acorda Therapeutics, Inc
  • Paul J. Hastings Vice Chair
    Chairman and CEO, OncoMed Pharmaceuticals, Inc
  • Rachel K. King Immediate Past Chair
    President & CEO, GlycoMimetics, Inc
  • Michael Narachi Secretary
    President and CEO, Orexigen Therapeutics, Inc
  • Mark Alles
    Chief Executive Officer, Celgene Corporation
  • Stuart A. Arbuckle
    Executive Vice President and Chief Commercial Officer, Vertex Pharmaceuticals Incorporated
  • Alex M. Azar II
    President of Lilly USA, Eli Lilly and Company
  • Martin Babler
    Chief Executive Officer, Principia Biopharma
  • Jean-Jacques Bienaime
    President & CEO, BioMarin Pharmaceutical, Inc
  • Chris Boerner
    President and Head of US Commercial Business, Bristol-Myers Squibb Company
  • Albert Bourla
    Group President of Global Innovative Pharma Global Vaccines Oncology&Consumer, Pfizer Inc.
  • Ian T. Clark
    CEO & Head of North American Commercial Operations, Genentech, Genentech, A Member of the Roche Group
  • Habib Dable
    President, U.S. Pharmaceuticals, Bayer Corporation
  • Douglas A. Doerfler
    President & CEO, MaxCyte, Inc
  • Paul R. Eisenberg, MD, MPH
    Senior Vice President of Global Regulatory Affairs and Safety, Amgen Inc.
  • Mark Enyedy
    President & CEO, ImmunoGen, Inc
  • William Fitzsimmons, PharmD, MS
    Divisional EVP for Global Regulatory Affairs & Global Clinical &Research Quality, Astellas Pharma Inc.
  • Julie L. Gerberding, MD, MPH
    EVP, Strategic Communications, Global Public Policy, and Population Health, Merck
  • John Glasspool
    EVP & Head of Corporate Strategy & Customer Operations , Baxalta
  • Glenn Gormley, MD, PhD
    President, Daiichi Sankyo Pharma Development
  • Maxine Gowen, PhD
    President & CEO, Trevena, Inc.
  • Peter S. Greenleaf
    Chairman & CEO, Sucampo Pharmaceuticals, Inc
  • David Hallal
    Chief Executive Officer, Alexion Pharmaceuticals, Inc
  • Jeffrey S. Hatfield
    Chief Executive Officer, Vitae Pharmaceuticals, Inc
  • Russell H. Herndon
    President & CEO, Hydra Biosciences, Inc
  • Bill Hinshaw
    Executive Vice President and Head, Novartis Oncology
  • Herve Hoppenot
    President & CEO, Incyte Corporation
  • Scott Koenig, MD, PhD
    President & CEO, MacroGenics, Inc
  • Joseph LaRosa
    Senior Vice President, General Counsel and Secretary, Regeneron Pharmaceuticals, Inc
  • Nick Leschly
    President & Chief Executive Officer, bluebird bio
  • Jeremy M. Levin , DPHIL,MB,BCHIR
    Chairman & CEO, Ovid Therapeutics Inc.
  • Elizabeth Lewis
    Chief Counsel, Global Oncology Business Unit, Patient Advocacy, Takeda Oncology
  • Sabine Luik, MD, MPH
    Senior Vice President, Medicine and Regulatory Affairs, Boehringer Ingelheim
  • John Maraganore, PhD
    Chief Executive Officer, Alnylam Pharmaceuticals, Inc
  • Thomas P. Mathers
    Chief Executive Officer, CoLucid Pharmaceuticals, Inc
  • Kiran Mazumdar-Shaw
    Chairperson & Managing Director, Biocon Limited
  • David P. Meeker, MD
    Chief Executive Officer, Genzyme Corporation, A Sanofi Company
  • Steven J. Mento, PhD
    President & CEO, Co-Founder, Conatus Pharmaceuticals, Inc
  • John F. Milligan, PhD
    President & CEO, Gilead Sciences, Inc
  • C. David Nicholson, PhD
    Chief R&D Officer, Allergan PLC
  • John A. Orwin
    President & CEO, Relypsa, Inc
  • Adelene Q. Perkins
    President & CEO, Infinity Pharmaceuticals, Inc.
  • Richard Pops
    Chairman & CEO, Alkermes, Inc.
  • Robert Repella
    Executive Vice President, Global Commercial Operations, CSL Behring
  • Howard W. Robin
    President & CEO, Nektar Therapeutics, Inc
  • James Sapirstein, RPh, MBA
    Chief Executive Officer, Contravir Pharmaceuticals
  • Michael Severino, MD
    EVP, Research and Development (R&D) and CSO, AbbVie Inc.
  • Jay P. Siegel, MD
    Chief Biotechnology Officer & Head, Scientific Strategy & Policy, Johnson & Johnson
  • Mark Skaletsky
    Chairman & CEO, Fenway Pharmaceuticals, Inc
  • Moncef Slaoui, PhD
    Chairman of GSK Vaccines, GlaxoSmithKline plc
  • Julie A. Smith
    President & CEO, Raptor Pharmaceutical Corporation
  • David M. Stack
    President & CEO, Pacira Pharmaceuticals, Inc.
  • Jean-Christophe Tellier
    Chief Executive Officer & Chairman, UCB SA
  • Henri A. Termeer
    Chairman of the Board, AVEO Oncology
  • Mark Timney
    President & CEO, Purdue Pharma LP
  • Kathleen Tregoning
    Senior Vice President, Government Affairs, Biogen
  • Gil Van Bokkelen, PhD
    Chairman & CEO, Athersys, Inc
  • Harold E. Van Wart, PhD
    President, CEO & Director, CymaBay Therapeutics
  • Neil K. Warma
    President & CEO, Opexa Therapeutics
  • H. Thomas Watkins Immediate Past Chair
    Chair Emeritus, BIO, Biotechnology Innovation Organization
  • Allen Waxman
    Executive Vice President & General Counsel, Eisai, Inc
  • Edward Williams
    Senior Vice President, BioPharmaceuticals Business Unit, Novo Nordisk
  • Rick E. Winningham
    Chief Executive Officer, Theravance Biopharma US, Inc.
  • Gary Zieziula
    President & Managing Director, North America, EMD Serono, Inc
  • Industrial & Environmental Section Governing Board

  • Alan Shaw, PhD I&E Section Chair
    President & CEO, Calysta
  • Tjerk de Ruiter I&E Section Vice Chair
    Chief Executive Officer, Corbion
  • Eli Ben-Shoshan
    Director – Strategy, Business Development, Mergers & Acquisitions, DuPont Industrial Biosciences
  • Doug Berven
    Vice President, Corporate Affairs, Poet, LLC
  • Neil Goldsmith
    CEO, Evolva
  • Jennifer Holmgren, PhD, MBA
    Chief Executive Officer, LanzaTech
  • Mark Jones, PhD
    Executive Strategy and Communications Director, The Dow Chemical Company
  • Michael Knutzen
    Global Program Director, PlantBottle, The Coca-Cola Company
  • James Levine
    Chief Executive Officer, Sapphire Energy, Inc.
  • John G. Melo
    Chief Executive Officer, Amyris, Inc.
  • Adam Monroe
    President, Americas, Novozymes
  • Markus Pompejus
    VP White Biotechnology Research North America, BASF Corporation
  • Anna Rath
    President & CEO, NexSteppe
  • Joseph Shaulson
    President & CEO, Metabolix, Inc
  • Stephan B. Tanda
    Managing Board Member, DSM Pharmaceutical Products
  • Jonathan S. Wolfson, JD, MBA
    Chief Executive Officer, TerraVia
  • Roger Wyse
    Managing Director, Spruce Capital Partners